Comparison of adverse events associated with different spacers used with non-extrafine beclometasone dipropionate for asthma.

ABSTRACT: Co-prescription of Aerochamber^® spacer with non-extrafine beclometasone diproprionate (non-EF BDP) is common but unlicensed. We report a comparison of inhaled corticosteroid (ICS)-related adverse events between patients co-prescribed Aerochamber compared to the licensed Volumatic^® spacer. We utilised two historical cohorts: questionnaire-based and electronic medical record (EMR)-based, to assess patient-reported and EMR-recorded adverse events in patients with asthma prescribed non-EF BDP. Marginal effect estimate (MEE) was calculated to determine non-inferiority of Aerochamber compared to Volumatic in terms of patient-reported oral thrush and hoarseness with margin of 0.13. Other patient-reported adverse events (sore throat, bruising, weight gain, and coughing), and

SUBMITTER: Ming SWY 

PROVIDER: S-EPMC6368625 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature